Innovation Pharma Subsidiary Secures Acceptance of New Drug Application for Secukinumab Injection

Stock News06-18

An announcement has been made by Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) regarding its subsidiary.

The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has recently received a formal acceptance notice from the National Medical Products Administration (NMPA).

The marketing application for its Secukinumab Injection has been officially accepted for review.

Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds to IL-17A, thereby blocking its interaction with the IL-17A receptor.

IL-17A is identified as a key cytokine in the inflammatory response and disease progression of conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis, playing a central role in their pathogenesis.

Functioning as an IL-17A inhibitor, Secukinumab specifically neutralizes IL-17A, suppressing its pro-inflammatory effects.

This action is effective in alleviating disease symptoms, providing sustained clinical improvement, and delivering long-term clinical benefits to patients.

Its fully human structure is associated with a lower incidence of anti-drug antibodies, offering a combination of durable efficacy and a favorable safety profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112530708?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 18:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112530708","market":"hk","top_or_hot":-1,"title":"Innovation Pharma Subsidiary Secures Acceptance of New Drug Application for Secukinumab Injection","media":"Stock News","content":"<p>An announcement has been made by <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (<b>300765.SZ</b>) regarding its subsidiary.<br><br>The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has recently received a formal acceptance notice from the National Medical Products Administration (NMPA).<br><br>The marketing application for its Secukinumab Injection has been officially accepted for review.<br><br>Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds to IL-17A, thereby blocking its interaction with the IL-17A receptor.<br><br>IL-17A is identified as a key cytokine in the inflammatory response and disease progression of conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis, playing a central role in their pathogenesis.<br><br>Functioning as an IL-17A inhibitor, Secukinumab specifically neutralizes IL-17A, suppressing its pro-inflammatory effects.<br><br>This action is effective in alleviating disease symptoms, providing sustained clinical improvement, and delivering long-term clinical benefits to patients.<br><br>Its fully human structure is associated with a lower incidence of anti-drug antibodies, offering a combination of durable efficacy and a favorable safety profile.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovation Pharma Subsidiary Secures Acceptance of New Drug Application for Secukinumab Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovation Pharma Subsidiary Secures Acceptance of New Drug Application for Secukinumab Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-18 18:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement has been made by <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (<b>300765.SZ</b>) regarding its subsidiary.<br><br>The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has recently received a formal acceptance notice from the National Medical Products Administration (NMPA).<br><br>The marketing application for its Secukinumab Injection has been officially accepted for review.<br><br>Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds to IL-17A, thereby blocking its interaction with the IL-17A receptor.<br><br>IL-17A is identified as a key cytokine in the inflammatory response and disease progression of conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis, playing a central role in their pathogenesis.<br><br>Functioning as an IL-17A inhibitor, Secukinumab specifically neutralizes IL-17A, suppressing its pro-inflammatory effects.<br><br>This action is effective in alleviating disease symptoms, providing sustained clinical improvement, and delivering long-term clinical benefits to patients.<br><br>Its fully human structure is associated with a lower incidence of anti-drug antibodies, offering a combination of durable efficacy and a favorable safety profile.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300765","symbol_name":"石药创新","start_time":0,"source_url":"","article_id":"1112530708","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112530708","pubTimestamp":1781778873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement has been made by Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) regarding its subsidiary.The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","IPOS":"Renaissance International IPO ETF","BK0226":"食品制造"},"translate_title":"Innovation Pharma子公司获得司库奇尤单抗注射液新药申请受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"IPOS":1},"content_text":"An announcement has been made by Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) regarding its subsidiary.The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has recently received a formal acceptance notice from the National Medical Products Administration (NMPA).The marketing application for its Secukinumab Injection has been officially accepted for review.Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds to IL-17A, thereby blocking its interaction with the IL-17A receptor.IL-17A is identified as a key cytokine in the inflammatory response and disease progression of conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis, playing a central role in their pathogenesis.Functioning as an IL-17A inhibitor, Secukinumab specifically neutralizes IL-17A, suppressing its pro-inflammatory effects.This action is effective in alleviating disease symptoms, providing sustained clinical improvement, and delivering long-term clinical benefits to patients.Its fully human structure is associated with a lower incidence of anti-drug antibodies, offering a combination of durable efficacy and a favorable safety profile.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112530708","isCrawlerRequest":true}